Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Trigone intravesical sustained release formulation of gemcitabine and docetaxel could represent the true innovation in the care of high grade non-muscle invasive bladder cancer. Number two ...

“We believe Trigone’s novel intravesicular sustained-release formulation could enable NDV-01 to be a first-line therapy for non-muscle invasive bladder cancer, supported by several ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 ...